{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-130283","form_type":"8-K","ticker":"OKUR","cik":"0001637715","company_name":"OnKure Therapeutics, Inc.","filed_at":"2026-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.712367+00:00","generated_at":"2026-05-15T08:23:52.535634+00:00","sec_items":["1.01","3.02","5.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"OnKure raises $150M in PIPE; plans IND filings for PI3Kα pan-mutant inhibitors in H1 2027","bullets":["Private placement of ~26.7M shares at $4.15 and ~9.4M pre-funded warrants; gross proceeds ~$150M.","Proceeds to fund development of PI3Kα pan-mutant inhibitors OKI-345 (breast cancer) and OKI-355 (vascular anomalies).","IND submissions for OKI-345 and OKI-355 planned for H1 2027; no further independent development of OKI-219.","Dr. Liam Ratcliffe appointed to board effective at closing, designated by lead investor AI Biotechnology.","Officers/directors and company subject to 180-day lock-up (or until registration effective) on share issuance/sales."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-130283","json":"https://secwatch.observer/filing/0001193125-26-130283.json","markdown":"https://secwatch.observer/filing/0001193125-26-130283.md","text":"https://secwatch.observer/filing/0001193125-26-130283.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1637715/000119312526130283/0001193125-26-130283-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1637715/000119312526130283/d910791d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:23:52.535634+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"930c2ec954fdcf3cb09e72439f9326094ff1d0a0","claim":"OnKure Therapeutics, Inc. entered into Purchase Agreement with certain institutional accredited investors valued at approximately $150.0 million (effective 2026-03-27).","evidence_excerpt":"On March 27, 2026, OnKure Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement (i) 26,713,636 shares (the “Shares”) of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”), at a purchase price of $4.15 per Share, and (ii) pre-funded warrants (the “Pre-Funded Warrants” and together with the Shares, the “Securities”) to purchase 9,430,959 shares of Common Stock (the “Warrant Shares”), at a purchase price of $4.1499 per underlying Warrant Share (the “Private Placement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312526130283/0001193125-26-130283-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional accredited investors"},{"label":"Value","value":"approximately $150.0 million"},{"label":"Effective","value":"2026-03-27"}]},{"claim_id":"be41db4e9c04a1aea5f6b193fe57a1f33cd6e3f4","claim":"OnKure Therapeutics, Inc. entered into Registration Rights Agreement with the Company and the Investors (effective 2026-03-27).","evidence_excerpt":"the Company and the Investors also entered into a Registration Rights Agreement, dated March 27, 2026 (the “Registration Rights Agreement”), providing for the registration for resale of the Shares and the Warrant Shares, pursuant to a registration statement (the “Registration Statement”) to be filed with the SEC within 30 days after the Closing Date.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312526130283/0001193125-26-130283-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"the Company and the Investors"},{"label":"Effective","value":"2026-03-27"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}